BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Epilepsy and seizures clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for epilepsy: 91 (52 sponsors; 11 newly posted in the last 180 days, 6 stopped in the last 180 days; 5 new-entrant sponsors). Momentum score 17, rank 36 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 7, Phase 2 24, Phase 3 29, Phase 4 4, N/A 26.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Praxis Precision Medicines PRAX | 7 | P2 2, P3 5 | 0 | 3 |
| Xenon Pharmaceuticals Inc. XENE | 4 | P3 3, P2 1 | 0 | 1 |
| Longboard Pharmaceuticals | 3 | P3 3 | 0 | 1 |
| Jazz Pharmaceuticals JAZZ | 5 | P3 2, P4 2, NA 1 | 3 | 1 |
| Biohaven Therapeutics Ltd. BHVN | 4 | P2 1, P3 2, P1 1 | 0 | 2 |
| Rapport Therapeutics Inc. RAPP | 4 | P2 1, P1 1, P3 2 | 1 | 0 |
| Ono Pharmaceutical Co., Ltd. | 3 | P3 2, P2 1 | 0 | 2 |
| UCB Biopharma SRL | 3 | P3 2, NA 1 | 0 | 0 |
| Epygenix | 2 | P3 2 | 0 | 1 |
| Neurona Therapeutics | 2 | P2 1, P3 1 | 0 | 0 |
| SK Life Science, Inc. | 2 | P4 1, P3 1 | 0 | 1 |
| Stoke Therapeutics, Inc STOK | 2 | P3 1, P2 1 | 0 | 1 |
| Immedica Pharma AB | 1 | P3 1 | 0 | 0 |
| Oils4Cure | 1 | P3 1 | 0 | 0 |
| Zogenix, Inc. | 1 | P3 1 | 0 | 0 |
| Encoded Therapeutics | 3 | P2 3 | 0 | 0 |
| Supernus Pharmaceuticals, Inc. SUPN | 3 | P2 3 | 0 | 0 |
| Actio Biosciences, Inc. | 2 | P1 1, P2 1 | 1 | 2 |
| Epiminder America, Inc. | 2 | NA 2 | 0 | 0 |
| NaviFUS Corporation | 2 | NA 1, P2 1 | 0 | 1 |
| Neuronostics Ltd | 2 | NA 2 | 0 | 0 |
| NeuroPace NPCE | 2 | NA 1, P2 1 | 1 | 2 |
| Shanghai Zhimeng Biopharma, Inc. | 2 | P2 2 | 0 | 0 |
| Adraxe Corp. new entrant | 1 | EARLY_P1 1 | 1 | 0 |
| Aeovian Pharmaceuticals, Inc. new entrant | 1 | P2 1 | 1 | 0 |
New-entrant sponsors: Adraxe Corp., Aeovian Pharmaceuticals, Inc..
Recently stopped trials
- NCT05226780 Neurocrine Biosciences - terminated: This study was prematurely terminated due to sponsor decision. Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DE
- NCT03635073 Takeda - terminated: Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary da A Study of Soticlestat in Adults and Children With Rare Epilepsies
- NCT05163314 Takeda - terminated: Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary da A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
- NCT06422377 Takeda - terminated: Business decision unrelated to patient safety. A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to
- NCT06395792 Takeda - withdrawn: Business Decision A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, Teenagers and Adults in Portugal
- NCT06983158 Capsida Biotherapeutics, Inc. - terminated: Stopping rule for study was met A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P2 | NeuroPace NPCE | NCT05339126 RNS System LGS Feasibility Study | Epilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable; Seizures; Seizures, General | active not recruiting | 24 |
| 2026-11-30 est. | P1/P2 | UniQure Biopharma B.V. QURE | NCT06063850 AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | Mesial Temporal Lobe Epilepsy | recruiting | 12 |
| 2026-12 est. | P2/P3 | Biohaven Therapeutics Ltd. BHVN | NCT06132893 A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Focal Epilepsy | active not recruiting | 390 |
| 2026-12 est. | P2 | Biohaven Therapeutics Ltd. BHVN | NCT06443463 Long-term Safety and Tolerability of BHV-7000 | Focal Epilepsy | enrolling by invitation | 660 |
| 2026-12 est. | P3 | Praxis Precision Medicines PRAX | NCT07010471 A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | Developmental and Epileptic Encephalopathy 1 | active not recruiting | 160 |
| 2026-12 est. | P3 | Praxis Precision Medicines PRAX | NCT07019922 A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | Epileptic Encephalopathy; SCN2A Encephalopathy | recruiting | 40 |
| 2026-12-30 est. | P1/P2 | Supernus Pharmaceuticals, Inc. SUPN | NCT03474770 BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Focal Impaired Awareness Seizures | active not recruiting | 16 |
| 2026-12-31 est. | P3 | Longboard Pharmaceuticals | NCT06660394 A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | Dravet Syndrome | active not recruiting | 108 |
| 2027-01 est. | P3 | Praxis Precision Medicines PRAX | NCT07505004 Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | Focal Epilepsy | active not recruiting | 300 |
| 2027-01 est. | P2 | Actio Biosciences, Inc. | NCT07600736 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-relate | KCNT1-Related Epilepsy | recruiting | 61 |
| 2027-01-31 est. | P3 | Ono Pharmaceutical Co., Ltd. | NCT06579573 ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures. | Epilepsy, Generalized | recruiting | 15 |
| 2027-01-31 est. | P2 | Ono Pharmaceutical Co., Ltd. | NCT06590896 Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures | Epilepsies, Partial | recruiting | 100 |
| 2027-02 est. | P3 | SK Life Science, Inc. | NCT05219617 Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | Seizures; Lennox Gastaut Syndrome | recruiting | 252 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-01 est. | P3 | Epygenix | NCT05066217 An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | Lennox Gastaut Syndrome | recruiting | 260 |
| 2026-10-31 est. | P3 | Longboard Pharmaceuticals | NCT06719141 A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | Developmental and Epileptic Encephalopathy | active not recruiting | 367 |
| 2026-10-02 | P3 | SK Life Science, Inc. | NCT05067634 Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures | Partial Epilepsy | completed | 154 |
| 2026-10 est. | P2/P3 | Biohaven Therapeutics Ltd. BHVN | NCT06309966 Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Focal Epilepsy | active not recruiting | 390 |
| 2026-09-01 | P3 | UCB BIOSCIENCES, Inc. | NCT06118255 A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrom | Dravet Syndrome | completed | 25 |
| 2026-08-17 | P2 | NeuroPro Therapeutics, Inc. | NCT06769659 A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures | Epilepsy, Generalized; Epilepsy, Absence | completed | 14 |
| 2026-07-07 | P3 | UCB Biopharma SRL | NCT04666610 A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Ju | Childhood Absence Epilepsy; Juvenile Absence Epilepsy | completed | 154 |
| 2026-06-10 | P3 | SK Life Science, Inc. | NCT03961568 Cenobamate Open-Label Extension Study for YKP3089C025 | Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy | completed | 147 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "epilepsy"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.